We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Investors should be wary of the damages a long, drawn out legal battle can inflict
US drugmaker’s shares fall more than 30% as it blames weak demand for jabs
German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations
Europe may receive vaccines tailored to BA.4 and BA.5 sub-variants later than the US
Big Pharma group is using cash pile from sales of Covid-19 vaccines to replenish drug pipeline
Decision will allow Biden administration to tap new resources to combat disease amid criticism over its response
Move follows declarations of emergency by California and Illinois amid growing criticism of US government’s response
Quarterly figures beat expectations as pharma group strengthens pipeline of new drugs
Paxlovid dominates antiviral treatment market but weak demand could cause supply glut, data group says
US president has ‘very mild symptoms’ and is taking Pfizer antiviral pill
The latest strains have spread fast and governments are trying to catch up
Member states, BioNTech/Pfizer edge closer to deal to delay jab deliveries amid oversupply and rising case numbers
Strain has been detected in Germany, the Netherlands, Japan, the UK and the US
Infection rates in the UK today may well be higher than they have ever been
WHO and Unicef warn of fall in immunisations for diseases such as diphtheria, polio and measles
Antiviral treatment Paxlovid is being widely prescribed despite questions about its effectiveness
Public accounts committee praises jab campaign but warns almost 3mn people in England yet to be vaccinated
Recommendation comes as highly transmissible BA.5 Omicron sub-variant drives up infections across continent
Shots unused due to factors including hesitancy, improper storage and donations delivered close to expiry dates
The chair of the $60bn US biopharma group explains how his approach to combining science with entrepreneurship led to the company’s creation
Tie-up faces obstacles in current climate of aggressive watchdogs and concern over drug prices
Partnership with NIH agency is part of effort to expand global access to medicines
European regulators consider vaccinating babies and toddlers, but some question the value of targeting youngsters
US group attracted by approved drugs as it prepares to lose patent protection of Keytruda
Homegrown jabs are undergoing trials but may struggle against rapidly mutating virus
International Edition
